Looking back at July 2026, the global biotechnology industry ushered in an intensive financing boom, and the industry's innovative value continued to be recognized by the capital market. In the same month, a total of 15 global biotechnology companies completed a single large-scale financing of over 50 million US dollars, with a total financing amount exceeding 3 billion US dollars. The funds are highly focused on cutting-edge fields such as AI drug discovery, radiopharmaceuticals, gene editing, and neuroscience.
In this round of financing wave, the AI drug discovery track has performed outstandingly, relying on the advantages of efficient and low-cost new drug research and development, continuously harvesting large amounts of capital, and becoming a hot spot in the industry. Chai Discovery has completed a $400 million Series C funding round. Data shows that Chai Discovery builds artificial intelligence models to accelerate preclinical drug discovery, predict and reprogram interactions between molecules. Its vision is to create a "molecular computer-aided design suite", and it has launched artificial intelligence models Chai1 and Chai2, the latter of which has significantly improved its success rate in the field of de novo antibody design.
In the AI driven new drug development track, DeRui Zhiyao has also completed a cumulative $52 million Series B financing. The funds raised in this round of financing will be invested in the deep technological iteration of the company's self-developed full chain AI pharmaceutical engine MAP (Molecular Arts Platform), continuously improving the multi-agent collaborative system and clinical data in the Loop, and promoting the phase III clinical development and commercialization of the self-developed oral GLP-1RA small molecule MDR-001. MDR-001 is an AI assisted oral small molecule GLP-1 receptor agonist independently developed by Delphi Pharmaceuticals for obesity and type 2 diabetes. It only takes 4.5 years from project discovery to phase III.
The radiopharmaceutical track has also received significant financing. It is reported that AdvantCell, a clinical stage radiopharmaceutical company, has completed a $315 million Series D financing. This round of financing has received oversubscription and expanded its scale, which will be used to promote its lead-212 targeted alpha therapy pipeline, with a focus on supporting the main candidate drug ADVC001 to enter phase 3 clinical development of metastatic prostate cancer. ADVC001 is a lead-212 prostate-specific membrane antigen (PSMA) targeted alpha therapy under development for the treatment of metastatic prostate cancer, currently in phase 2 clinical development. This therapy aims to selectively deliver high-energy alpha rays to tumor cells while minimizing radiation exposure to healthy tissues.
In addition, gene editing, as a cutting-edge technology in the field of biomedicine, provides new solutions for the treatment of difficult diseases such as genetic diseases, tumors, and rare diseases, and has enormous potential for industry development. In July, the gene editing track saw multiple rounds of financing. If Scribe Therapeutics raises $156 million in a new round of funding, the company expects to use $30 million to $35 million from the IPO proceeds to advance the Phase 1 clinical study of STX-1150, and $15 million to $20 million to promote the clinical development of the APOC3 targeted therapy STX-1400 and obtain preliminary data. Among them, STX-1150 is an innovative drug aimed at persistently reducing LDL-C by silencing the transcription of cholesterol regulatory factor PCSK9.
Nava Therapeutics has completed a $89 million Series A funding round. It is reported that Nava has developed a new type of "immunotropic" ionizable lipid, whose chemical structure has been engineered to minimize ApoE adsorption and liver distribution. Nava's flagship pipeline NT-001 is an in vivo CAR-T candidate drug that targets CD19, integrating novel immunomodulatory ionizable lipids, CD8 targeting ligands, and mRNA encoding humanized CD19 CAR.
In the field of neuroscience, Mentari Therapeutics has completed a $200 million private equity financing. This round of capital injection will extend Mentari's cash reserve maintenance period until 2029 and support the company in advancing the release of Phase IIa data for two co lead candidate drugs: MT-001, an anti PACAP monoclonal antibody; And MT-002, a dual antibody that targets both CGRP and PACAP simultaneously. Both drugs are designed to treat chronic and episodic migraine.
From the above financing, it can be seen that capital is no longer blindly chasing popular concepts, but is highly focused on cutting-edge segmented tracks with high technological barriers, clear clinical value, and clear commercialization paths. The intensive financing of AI enabled fields such as pharmaceuticals, nuclear medicine, gene editing, and neuroscience not only confirms the trend of the global biopharmaceutical industry's transformation towards precision, intelligence, and source innovation, but also injects strong impetus into the industry's technological iteration and achievement transformation. In the future, with the continuous increase of capital and breakthroughs in technology, cutting-edge biotechnology will continue to rewrite the global medical landscape, bringing more innovative possibilities for the diagnosis and treatment of difficult diseases and the protection of life and health.